Discover how to manage your next RFP with confidence to secure better PBM rates, service and innovation programs. Watch this short, on-demand PBM RFP webinar.
Watch this short, on-demand audit webinar to learn how to protect yourself from unexpected liability and why it's important to create a PBM audit strategy.
Even though Medicare data validation is in its fifth year of audit, the validation standards remain complex and continue to evolve. The Coverage Determinations and Redeterminations reporting section, formally known as Coverage Determinations and Exceptions, went through many changes between 2013 and 2014. Some of these changes added additional reporting sections and others consolidated some of the elements.
Special needs plan (SNP) care management reporting is one of the most difficult data validation standards. The average SNP score in 2013 was only 96.4, the worst scoring section by a wide margin. (Part C Grievances was next at 98.)
Management and oversight of data validation varies between health plans. Different plans may use an audit department, a compliance unit or a Medicare oversight department. However your plan is structured, having a centralized business unit in charge of data validation reporting can ensure clear and effective communication to all stakeholders. Consider the following ideas to help make your 2015 review a success.
This is Part 2 of our 2014 data validation changes review. If you missed Part 1 you can view it HERE. In Part 1 we dealt with the data element changes for Part C. Part 2 will focus on Part D changes from the February 2014 Technical Specifications. Incorporating these changes is vital for plans to maximize their data validation scores.
The 2014 data validation audit has come to a close and I hope it was successful for you!
The Office of Inspector General (OIG) found that more than $33 million in prescription drug claims for hospice enrollees were paid twice in calendar year 2009: once under Medicare Part A and again under Part D. In response to the findings, Centers for Medicare and Medicaid Services (CMS) issued final 2014 guidance aimed at mitigating duplicate payments. The most significant change for sponsors is that, beginning May 1, plans should place beneficiary-level prior authorization (PA) requirements on all drugs for beneficiaries who elect hospice care.
Pricing guarantees are tricky. Even with a traditional arrangement (locked-in brand discounts and dispensing fees) you still have to account for generic pricing and aggregated guarantees often can’t be calculated until the end of the year. Measuring generic effective rates in the middle of a pricing term is difficult, too, and your PBM may argue that any sign of underperformance is not a cause for concern because the term is incomplete.
Brian Bullock, Founder and CEO at The Burchfield Group, presented his perspectives on prescription drug innovation at the Minnesota Health Action Group’s 7th Annual Leadership Summit, Moving Forward in Uncertain Times, on February 21.
In January CMS announced it proposed 2015 policy and technical changes for Medicare Advantage (MA) and Medicare Advantage Prescription Drug (MAPD) programs. Plan sponsors have until March 7 to provide comments and feedback about the changes. Proposed changes apply to:
© 2014 THE BURCHFIELD GROUP